STOCK TITAN

DURECT Corporation - $DRRX STOCK NEWS

Welcome to our dedicated page for DURECT Corporation news (Ticker: $DRRX), a resource for investors and traders seeking the latest updates and insights on DURECT Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DURECT Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DURECT Corporation's position in the market.

Rhea-AI Summary

DURECT (Nasdaq: DRRX) has received Breakthrough Therapy designation (BTD) from the FDA for larsucosterol, aimed at treating severe alcohol-associated hepatitis (AH). AH has no approved treatments and high mortality rates, making the designation crucial. The decision is backed by positive results from the Phase 2b AHFIRM trial. DURECT plans to initiate a Phase 3 clinical trial to confirm the efficacy and safety of larsucosterol. Detailed results will be presented at the EASL Congress 2024 in Milan on June 8, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.04%
Tags
-
Rhea-AI Summary

DURECT (Nasdaq: DRRX) announced its Q1 2024 financial results, showing $1.8 million in revenue and a net loss of $7.6 million, an improvement from the $12.0 million loss in Q1 2023. The company has $21.6 million in cash and investments, with a debt of $14.6 million as of March 31, 2024. The FDA's feedback supports a single pivotal Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH), with new Phase 3 protocol details expected later this year. DURECT will present Phase 2b AHFIRM trial data at the EASL Congress in June 2024. A webcast of the earnings call will be held today at 4:30 p.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.02%
Tags
-
Rhea-AI Summary

DURECT (Nasdaq: DRRX) will report its first quarter 2024 financial results on May 13, 2024. The company focuses on epigenetic therapies for severe conditions like organ injury and cancer. A conference call and webcast will follow to discuss the results and provide a corporate update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15%
Tags
Rhea-AI Summary

DURECT (Nasdaq: DRRX) announced a late-breaking oral presentation at the EASL Congress 2024 to discuss data from the Phase 2b AHFIRM trial on larsucosterol for severe alcohol-associated hepatitis. The presentation will be held on June 8, 2024, in Milan, Italy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
-
Rhea-AI Summary
DURECT (DRRX) reports financial results for Q4 and full year 2023, along with a business update. Ongoing communication with FDA for Larsucosterol in Alcohol-Associated Hepatitis. Webcast of earnings call on March 27th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.7%
Tags
-
Rhea-AI Summary
DURECT (Nasdaq: DRRX) will report its Q4 and full year 2023 financial results on March 27, 2024. The company focuses on epigenetic therapies for serious conditions like acute organ injury and cancer. Investors can join a conference call and webcast for updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) partners with Charles River Laboratories for a co-marketing and collaboration agreement to promote ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada. The partnership aims to jointly market and commercialize the product line over a multi-year period, leveraging Charles River's expertise in drug discovery and non-clinical development solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
none
-
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, virtually, on February 14, 2024. The company's President and CEO, James E. Brown, will be presenting. The webcast link is available on DURECT's homepage. Management will also be available for one-on-one meetings with institutional investors during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.04%
Tags
conferences
-
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) reported topline data from the AHFIRM trial, showing a promising efficacy signal in favor of larsucosterol in reducing mortality in alcohol-associated hepatitis (AH) patients. The company plans to discuss the trial results with the FDA in the first quarter of 2024 and potentially design a Phase 3 trial using mortality as the primary endpoint. Financially, total revenues were $1.7 million, with a net loss of $3.0 million for the three months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
Rhea-AI Summary
DURECT Corporation (Nasdaq: DRRX) to Report Q3 2023 Financial Results on November 13, 2023. The company will host a conference call and webcast to discuss financial results and provide a corporate update. Details for the call and webcast are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
DURECT Corporation

Nasdaq:DRRX

DRRX Rankings

DRRX Stock Data

53.08M
29.66M
5.97%
22.56%
3.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CUPERTINO

About DRRX

durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use